Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children

Pharmacogenomics

Volumn 16, Issue 10, 2015, Pages 1065-1076

  Visscher, Henk ^a   Rassekh, S Rod ^a   Sandor, George S ^a   Caron, Huib N ^b   Van Dalen, Elvira C ^b   Kremer, Leontien C ^b   Van Der Pal, Helena J ^b,c   Rogers, Paul C ^a   Rieder, Michael J ^d   Carleton, Bruce C ^e   Hayden, Michael R ^a   Ross, Colin J ^a,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anthracyclines; association study; cardiotoxicity; childhood cancer; pharmacogenomics

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DAUNORUBICIN; DOXORUBICIN; ORGANIC ANION TRANSPORTER 2; ANTHRACYCLINE; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; SLC22A17 PROTEIN, HUMAN; SLC22A7 PROTEIN, HUMAN;

ARTICLE; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PHARMACOGENETICS; PREDICTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SLC22A17 GENE; SLC22A7 GENE; SULT2B1 GENE; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLINICAL TRIAL; FEMALE; FOLLOW UP; GENETICS; HEART DISEASE; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; RISK;

ANTHRACYCLINES; CARDIOTOXICITY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEART DISEASES; HUMANS; MALE; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84941695988     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.61     Document Type: Article

References (53)

1. Mertens AC, Yasui Y, Neglia JP et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J. Clin. Oncol. 19(13), 3163-3172 (2001).
2. Van Dalen EC, Van Der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur. J. Cancer 42(18), 3191-3198 (2006).
3. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 94(4), 525-533 (2008).
4. Kremer LC, Van Der Pal HJ, Offringa M, Van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann. Oncol. 13(6), 819-829 (2002).
5. Lipshultz SE, Lipsitz SR, Sallan SE et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J. Clin. Oncol. 23(12), 2629-2636 (2005).
6. Van Der Pal HJ, Van Dalen EC, Hauptmann M et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch. Intern. Med. 170(14), 1247-1255 (2010).
7. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32(2), 302-314 (1973).
8. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern.Med. 91(5), 710-717 (1979).
9. Kremer LC, Van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann. Oncol. 13(4), 503-512 (2002).
10. Tukenova M, Guibout C, Oberlin O et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J. Clin. Oncol. 28(8), 1308-1315 (2010).
11. Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112(24), 3754-3762 (2005).
12. Rossi D, Rasi S, Franceschetti S et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia 23(6), 1118-1126 (2009).
13. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 112(12), 2789-2795 (2008).
14. Blanco JG, Sun CL, Landier W et al. Anthracyclinerelated cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology Group. J. Clin. Oncol. 30(13), 1415-1421 (2012).
15. Visscher H, Ross CJ, Rassekh SR et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr. Blood Cancer 60(8), 1375-1381 (2013).
16. Carleton B, Poole R, Smith M et al. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiol. Drug Saf. 18(8), 713-721 (2009).
17. Cancer Therapy Evaluation Program-Common Terminology Criteria for Adverse Events-Version 3. http://ctep.cancer.gov/reporting/ctc.html
18. Altman AJ. Children's Oncology Group. Supportive care of children with cancer: current therapy and guidelines from the Children's Oncology Group. (3rd). Johns Hopkins University Press, Baltimore, MD, USA (2004).
19. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74(1), 106-120 (2004).
20. Visscher H, Ross CJ, Dube MP et al. Application of principal component analysis to pharmacogenomic studies in Canada. Pharmacogenomics J. 9(6), 362-372 (2009).
21. Brown AM, Renaud Y, Ross C et al. Development of a broadbased ADME panel for use in pharmacogenomic studies. Pharmacogenomics 15(9), 1185-1195 (2014).
22. Bains OS, Grigliatti TA, Reid RE, Riggs KW. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J. Pharmacol. Exp. Ther. 335(3), 533-545 (2010).
23. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet. Epidemiol. 32(4), 361-369 (2008).
24. Robin X, Turck N, Hainard A et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011).
25. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch. 447(5), 666-676 (2004).
26. Cano-Soldado P, Pastor-Anglada M. Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Med. Res. Rev. 32(2), 428-457 (2012).
27. Okabe M, Unno M, Harigae H et al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun. 333(3), 754-762 (2005).
28. Okabe M, Szakacs G, Reimers MA et al. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol. Cancer Ther. 7(9), 3081-3091 (2008).
29. Heibein AD, Guo B, Sprowl JA, Maclean DA, Parissenti AM. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer 12, 381 (2012).
30. Bennett KM, Liu J, Hoelting C, Stoll J. Expression and analysis of two novel rat organic cation transporter homologs, SLC22A17 and SLC22A23. Mol. Cell Biochem. 352(1-2), 143-154 (2011).
31. Cropp CD, Komori T, Shima JE et al. Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol. Pharmacol. 73(4), 1151-1158 (2008).
32. Errasti-Murugarren E, Pastor-Anglada M. Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics 11(6), 809-841 (2010).
33. Heintzman ND, Stuart RK, Hon G et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39(3), 311-318 (2007).
34. Westra HJ, Peters MJ, Esko T et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45(10), 1238-1243 (2013).
35. Ji Y, Moon I, Zlatkovic J et al. Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics. J. Pharmacol. Exp. Ther. 322(2), 529-540 (2007).
36. Andrews PA, Brenner DE, Chou FT, Kubo H, Bachur NR. Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab. Dispos. 8(3), 152-156 (1980).
37. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271(7), 3460-3468 (1996).
38. Zhang Y, El-Sikhry H, Chaudhary KR et al. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. 297(1), H37-H46 (2009).
39. Yee SB, Pritsos CA. Reductive activation of doxorubicin by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. Chem. Biol. Interact. 104(2-3), 87-101 (1997).
40. Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B. New developments in anthracycline-induced cardiotoxicity. Curr. Med. Chem. 16(13), 1656-1672 (2009).
41. Zhang S, Liu X, Bawa-Khalfe T et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18(11), 1639-1642 (2012).
42. L'ecuyer T, Allebban Z, Thomas R, Vander Heide R. Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am. J. Physiol. Heart Circ. Physiol. 286(6), H2057-H2064 (2004).
43. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Invest. 98(5), 1253-1260 (1996).
44. Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J. Biol. Chem. 271(21), 12610-12616 (1996).
45. Gao J, Xiong Y, Ho YS et al. Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity. Biochim. Biophys. Acta 1783(10), 2020-2029 (2008).
46. Bienengraeber M, Olson TM, Selivanov VA et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat. Genet. 36(4), 382-387 (2004).
47. Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 6, CD003917 (2011).
48. Lubieniecka JM, Liu J, Heffner D et al. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy. Cancer Epidemiol. Biomarkers Prev. 21(11), 2118-2120 (2012).
49. Armenian SH, Ding Y, Mills G et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br. J. Haematol. 163(2), 205-213 (2013).
50. Jungsuwadee P, Zhao T, Stolarczyk EI et al. The G671V variant of MRP1/ABCC1 links doxorubicin-induced acute cardiac toxicity to disposition of the glutathione conjugate of 4-hydroxy-2-trans-nonenal. Pharmacogenet. Genomics 22(4), 273-284 (2012).
51. Janssens AC, Aulchenko YS, Elefante S, Borsboom GJ, Steyerberg EW, Van Duijn CM. Predictive testing for complex diseases using multiple genes: fact or fiction? Genet. Med. 8(7), 395-400 (2006).
52. Van Dalen EC, Van Der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst. Rev. 4, CD005008 (2009).
53. Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst. Rev. 5, CD005006 (2010).